IMDRF Publishes AIMD Risk Categorization Framework — January 2026

What Was Published

The IMDRF Active Implantable Medical Devices (AIMD) Working Group released:

IMDRF/AIMD WG/N91 FINAL:2026 — Risk Categorization Framework for Active Implantable Medical Devices

This framework provides:

• Harmonized AIMD classification criteria
• Risk-based regulatory approach guidance
• Cross-jurisdictional consistency targets
• Implementation timeline expectations

What Is an AIMD

Examples:

• Cardiac pacemakers
• Implantable cardioverter-defibrillators (ICDs)
• Implantable neurostimulators
• Implantable insulin pumps
• Cochlear implants
• Implantable cardiac monitors

The 4-Tier Classification Framework

IMDRF's framework defines 4 risk tiers based on:

• Patient harm potential if device fails
• Reversibility of harm
• Vulnerability of patient population
• Healthcare system burden

Tier 1: Highest Risk (Life-Sustaining)

• Failure causes death or serious harm within hours
• Examples: Pacemakers (pacing-dependent patients), ICDs
• Regulatory expectation: Highest evidence burden, intensive PMS

Tier 2: High Risk (Life-Supporting)

• Failure causes serious harm within days
• Examples: Implantable insulin pumps, deep brain stimulators
• Regulatory expectation: High clinical evidence, structured PMS

Tier 3: Moderate Risk (Therapeutic Critical)

• Failure causes significant but recoverable harm
• Examples: Cochlear implants, implantable cardiac monitors
• Regulatory expectation: Solid clinical evidence, standard PMS

Tier 4: Lower Risk (Therapeutic Supportive)

• Failure causes manageable harm
• Examples: Some implantable drug delivery systems, vagal nerve stimulators (non-critical indications)
• Regulatory expectation: Standard clinical evidence

How Framework Affects Existing Classifications

FDA

FDA currently classifies AIMDs as Class III. IMDRF framework suggests:

• Tier 1: Continues PMA pathway
• Tier 2: PMA pathway with potential streamlining
• Tier 3-4: Some categories may transition to De Novo or 510(k) with substantial equivalence

EU MDR

EU MDR classifies all AIMDs as Class III. IMDRF framework suggests:

• Tier 1-2: Class III with intensive scrutiny
• Tier 3-4: Class III with proportional scrutiny

MFDS (Korea)

Korean classification typically aligns with EU/FDA. IMDRF framework suggests:

• Tier 1-2: Class IV
• Tier 3-4: Class III

PMDA (Japan)

Japanese classification typically Class IV for AIMDs. IMDRF framework may influence future updates.

Implementation Timeline

IMDRF frameworks are not regulations themselves; they influence regulator implementations:

Regulator	Expected Implementation
FDA	Guidance review 2026-2027
EU	MDCG guidance 2026-2027
MFDS	Korean guideline update 2027
PMDA	Review 2026-2027

Manufacturers should anticipate harmonization moves over 2026-2028.

What Manufacturers Should Do

Action 1: Review AIMD Portfolio

• Map current AIMDs to IMDRF tiers
• Identify devices that may benefit from streamlined pathway
• Identify devices with intensified expectations

Action 2: Anticipate Regulator Adoption

• Monitor FDA, EU MDR, MFDS guidance updates
• Prepare for potential pathway changes
• Build flexibility into regulatory strategy

Action 3: Strengthen Clinical Evidence

For AIMDs across all tiers, framework emphasizes:

• Real-world performance evidence
• Long-term follow-up data
• Pediatric/elderly subgroup analysis where applicable
• Cybersecurity for connected AIMDs

AIMD Cybersecurity Specific Considerations

Framework addresses cybersecurity for connected AIMDs:

• Threat modeling expected at all tiers
• SBOM mandatory for Tier 1-2 connected AIMDs
• Post-market vulnerability monitoring required
• Coordinated disclosure processes formalized

This aligns with FDA Section 524B, EU MDR cybersecurity guidance, and MFDS Notice 2026-12.

Korean-Specific Implications

Korean AIMD Market

Korean implantable cardiac device market: ~$200M annually. Korean neuromodulation market: ~$80M annually.

Korean Regulatory Implications

MFDS aligned with EU MDR for AIMD classification. IMDRF framework adoption expected by 2027.

Korean Reimbursement

Higher-tier AIMDs typically command premium HIRA reimbursement. NECA HTA frequently required.

Frequently Asked Questions

Q: Does IMDRF framework apply immediately?

A: No. IMDRF frameworks are guidance for regulators; not directly enforceable. Regulators adopt framework through their own implementation.

Q: How does this affect AIMDs already approved?

A: No immediate impact. Reclassification possible during future renewals or significant changes.

Q: Does the framework cover non-implantable active devices?

A: No. Framework specific to AIMDs. Separate IMDRF frameworks address other device categories (SaMD, IVD, etc.).

Q: When will MFDS adopt the framework?

A: MFDS typically adopts IMDRF guidance with 12–24 month delay. Expected 2027 Korean implementation.

Q: Does Leanabl support AIMD market entry?

A: Yes. Leanabl supports AIMD market entry in Korea, with regulatory strategy aligned with current Korean classification and anticipated IMDRF-influenced changes.

How Leanabl Helps

• Korea Medical Device Registration — AIMD Korean entry
• Regulatory Pathway Strategy — strategy under evolving framework
• Medical Device Cybersecurity — for connected AIMDs

Contact Leanabl for AIMD strategy.

---

Last updated: 2026-01-22.